174630-04-7

174630-04-7 structure

Name: Reversin 121
Chemical Name: 2-Methyl-2-propanyl (2S)-6-{[(benzyloxy)carbonyl]amino}-2-{[(2S)- 4-(benzyloxy)-2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-4-oxo butanoyl]amino}hexanoate (non-preferred name)
CAS Number: 174630-04-7
Molecular Formula: C₃₄H₄₇N₃O₉
Molecular Weight: 641.75200
Catalog: Signaling Pathways Membrane Transporter/Ion Channel P-glycoprotein
Create Date: 2016-03-04 14:31:48
Modify Date: 2024-04-05 10:44:12
Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers[1][2].

Name	2-Methyl-2-propanyl (2S)-6-{[(benzyloxy)carbonyl]amino}-2-{[(2S)- 4-(benzyloxy)-2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-4-oxo butanoyl]amino}hexanoate (non-preferred name)

Description	Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein
Target	P-glycoprotein[1]
In Vitro	Reversin 121 (12 μg/mL) (with gemcitabine (HY-17026)) reduces the proportions of tumor cells positive for MDR proteins in Panc1 cell[1]. Reversin 121 (5 μM) reverses the resistance against paclitaxel in paclitaxel-resistant NCI-H460 cell[2]. Reversin 121 (10 μM, 48 h) inhibits T cell proliferation[3].
In Vivo	Reversin 121 (2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day, i.p.) decreases tumor size and prevalence of metastases[1]. Animal Model: Orthotopic pancreatic carcinoma mouse model[1]. Dosage: 2.5 mg/kg, plus 5-fluorouracil, 35 mg/kg/day Administration: Intraperitoneal injection (i.p.), 5 days a week Result: Decreased in MRP3-positive cells.